{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T04:10:12Z","timestamp":1771647012514,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Key Research and Development Project of Department of Science and Technology, Sichuan Province","award":["2023YFS0307"],"award-info":[{"award-number":["2023YFS0307"]}]},{"name":"1\u00b73\u00b75 project for disciplines of excellence\u2013Clinical Research Incubation Project, West China Hospital, Sichuan University","award":["2023HXFH007"],"award-info":[{"award-number":["2023HXFH007"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00277-024-06097-w","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T08:58:43Z","timestamp":1732611523000},"page":"5315-5323","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Venetoclax plus D-CAG (decitabine, cytarabine, aclarubicin, G-CSF) for elderly or unfit patients with newly diagnosed acute myeloid leukemia: a multicenter, prospective study"],"prefix":"10.1007","volume":"103","author":[{"given":"Hongbing","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiwen","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianjun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YunFan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duanzhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuping","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,26]]},"reference":[{"issue":"11","key":"6097_CR1","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1002\/ajh.25975","volume":"95","author":"EH Estey","year":"2020","unstructured":"Estey EH (2020) Acute myeloid leukemia: 2021 update on risk-stratification and management. Am J Hematol 95(11):1368\u20131398. https:\/\/doi.org\/10.1002\/ajh.25975","journal-title":"Am J Hematol"},{"issue":"7","key":"6097_CR2","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH et al (2020) Azacitidine and Venetoclax in previously untreated Acute Myeloid Leukemia. N Engl J Med 383(7):617\u2013629 https:\/\/doi.org\/10.1056\/NEJMoa2012971","journal-title":"N Engl J Med"},{"key":"6097_CR3","doi-asserted-by":"publisher","unstructured":"Wang H, Mao L, Yang M, Qian P, Lu H, Tong H et al (2022) Venetoclax plus 3\u2009+\u20097 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial. Lancet Haematol 9(6): e415-e424. https:\/\/doi.org\/10.1016\/S2352-3026(22)00106-5","DOI":"10.1016\/S2352-3026(22)00106-5"},{"key":"6097_CR4","doi-asserted-by":"publisher","unstructured":"Kadia TM, Reville PK, Borthakur G, Yilmaz M, Kornblau S, Alvarado Y et al (2021) Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematol 8(8): e552-e561.https:\/\/doi.org\/10.1016\/S2352-3026(21)00192-7","DOI":"10.1016\/S2352-3026(21)00192-7"},{"issue":"25","key":"6097_CR5","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1200\/JCO.20.03736","volume":"39","author":"CD DiNardo","year":"2021","unstructured":"DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Xiao L, Kadia T et al (2021) Venetoclax Combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory Acute Myeloid Leukemia. J Clin Oncol 39(25):2768\u20132778 https:\/\/doi.org\/10.1200\/JCO.20.03736","journal-title":"J Clin Oncol"},{"issue":"33","key":"6097_CR6","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.1200\/JCO.21.02823","volume":"40","author":"TM Kadia","year":"2022","unstructured":"Kadia TM, Reville PK, Wang X, Rausch CR, Borthakur G, Pemmaraju N et al (2022) Phase II study of Venetoclax added to Cladribine Plus Low-Dose Cytarabine Alternating with 5-Azacitidine in older patients with newly diagnosed Acute myeloid leukemia. J Clin Oncol 40(33):3848\u20133857 https:\/\/doi.org\/10.1200\/JCO.21.02823","journal-title":"J Clin Oncol"},{"key":"6097_CR7","doi-asserted-by":"publisher","unstructured":"McCurdy SR, Luger SM (2021) Dose intensity for induction in acute myeloid leukemia: what, when, and for whom? Haematologica 106(10): 2544\u20132554. https:\/\/doi.org\/10.3324\/haematol.2020.269134","DOI":"10.3324\/haematol.2020.269134"},{"issue":"1","key":"6097_CR8","first-page":"10","volume":"9","author":"K Yamada","year":"1995","unstructured":"Yamada K, Furusawa S, Saito K, Waga K, Koike T, Arimura H et al (1995) Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: a pilot study. Leukemia 9(1):10\u201314","journal-title":"Leukemia"},{"key":"6097_CR9","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1756-8722-4-46","volume":"4","author":"G Wei","year":"2011","unstructured":"Wei G, Ni W, Chiao JW, Cai Z, Huang H, Liu D (2011) A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome. J Hematol Oncol 4:46. https:\/\/doi.org\/10.1186\/1756-8722-4-46.","journal-title":"J Hematol Oncol"},{"issue":"12","key":"6097_CR10","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1007\/s00277-012-1550-y","volume":"91","author":"LX Song","year":"2012","unstructured":"Song LX, Xu L, Li X, Chang CK, Zhang Y, Wu LY et al (2012) Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin\/cytarabine for patients with refractory acute myeloid leukemia. Ann Hematol 91(12):1879\u20131886. https:\/\/doi.org\/10.1007\/s00277-012-1550-y.","journal-title":"Ann Hematol"},{"issue":"1","key":"6097_CR11","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s00277-015-2505-x","volume":"95","author":"R Zheng","year":"2016","unstructured":"Zheng R, Xie B, Wang C, Yu B, Xu J, Tan H (2016) D-CAG (decitabine followed by cytarabine, aclarubicin, and G-CSF) for relapsed acute myeloid leukemia after hematopoietic cell transplantation. Ann Hematol 95(1):157\u2013159 https:\/\/doi.org\/10.1007\/s00277-015-2505-x","journal-title":"Ann Hematol"},{"issue":"2","key":"6097_CR12","doi-asserted-by":"publisher","first-page":"494","DOI":"10.19746\/j.cnki.issn.1009-2137.2019.02.030","volume":"27","author":"JL Zhang","year":"2019","unstructured":"Zhang JL, Cao YP, Li JG, [Efficacy, Safety of Decitabine Combined with CAG, Cytarabine (2019) Aclarubicin, G-CSF) for patients with Intermediate or High Risk Myelodysplastic Syndrome and Acute myeloid leukemia: a Meta-analysis]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 27(2):494\u2013503. https:\/\/doi.org\/10.19746\/j.cnki.issn.1009-2137.2019.02.030.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"30","key":"6097_CR13","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.1200\/JCO.20.00572","volume":"38","author":"CC Chua","year":"2020","unstructured":"Chua CC, Roberts AW, Reynolds J, Fong CY, Ting SB, Salmon JM et al (2020) Chemotherapy and Venetoclax in Elderly Acute myeloid leukemia trial (CAVEAT): a phase ib dose-escalation study of Venetoclax Combined with modified intensive chemotherapy. J Clin Oncol 38(30):3506\u20133517 https:\/\/doi.org\/10.1200\/JCO.20.00572","journal-title":"J Clin Oncol"},{"issue":"20","key":"6097_CR14","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391\u20132405 https:\/\/doi.org\/10.1182\/blood-2016-03-643544","journal-title":"Blood"},{"issue":"11","key":"6097_CR15","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1038\/sj.leu.2401573","volume":"13","author":"M Andreeff","year":"1999","unstructured":"Andreeff M, Jiang S, Zhang X, Konopleva M, Estrov Z, Snell VE et al (1999) Expression of bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid. Leukemia 13(11):1881\u20131892 https:\/\/doi.org\/10.1038\/sj.leu.2401573","journal-title":"Leukemia"},{"key":"6097_CR16","doi-asserted-by":"publisher","unstructured":"Leukemia, Lymphoma Group CSoHCMA (2021). [Chinese guidelines for the diagnosis and treatment of adult acute myeloid leukemia (not APL) ]. Zhonghua Xue Ye Xue Za Zhi 42(8): 617\u2013623. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2021.08.001","DOI":"10.3760\/cma.j.issn.0253-2727.2021.08.001"},{"issue":"1","key":"6097_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10(1):1\u201310. https:\/\/doi.org\/10.1016\/0197-2456(89)90015-9.","journal-title":"Control Clin Trials"},{"issue":"8","key":"6097_CR18","doi-asserted-by":"publisher","first-page":"6448","DOI":"10.18632\/oncotarget.3361","volume":"6","author":"J Li","year":"2015","unstructured":"Li J, Chen Y, Zhu Y, Zhou J, Xu Y, Li Y et al (2015) Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia. Oncotarget 6(8):6448\u20136458 https:\/\/doi.org\/10.18632\/oncotarget.3361","journal-title":"Oncotarget"},{"key":"6097_CR19","doi-asserted-by":"publisher","unstructured":"Huang J, Zhao H, Hong M, Zhu H, Zhu Y, Lian Y et al (2018) Early recovery of the platelet count after decitabine-based induction chemotherapy is a prognostic marker of superior response in elderly patients with newly diagnosed acute myeloid leukaemia. BMC Cancer 18(1): 1269. https:\/\/doi.org\/10.1186\/s12885-018-5160-5","DOI":"10.1186\/s12885-018-5160-5"},{"issue":"7","key":"6097_CR20","doi-asserted-by":"publisher","first-page":"5792","DOI":"10.18632\/aging.102973","volume":"12","author":"M Hong","year":"2020","unstructured":"Hong M, Zhu H, Sun Q, Zhu Y, Miao Y, Yang H et al (2020) Decitabine in combination with low-dose cytarabine, aclarubicin and G-CSF tends to improve prognosis in elderly patients with high-risk AML. Aging 12(7):5792\u20135811 https:\/\/doi.org\/10.18632\/aging.102973","journal-title":"Aging"},{"key":"6097_CR21","doi-asserted-by":"publisher","unstructured":"Liu MM, Zhang Y, Zheng WY, Liu QF (2020) DAC\u2009+\u2009CAG Compared with the Standard 3\u2009+\u20097 Regimen for Induction of the Medically Fit Elderly Acute Myeloid Leukemia: An Open-Label, Multicenter, Randomized, Phase III Trial. blood 136 (Supplement 1): 23. https:\/\/doi.org\/10.1182\/blood-2020-138396","DOI":"10.1182\/blood-2020-138396"},{"key":"6097_CR22","doi-asserted-by":"publisher","unstructured":"DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS et al (2019) Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133(1): 7\u201317. https:\/\/doi.org\/10.1182\/blood-2018-08-868752","DOI":"10.1182\/blood-2018-08-868752"},{"issue":"15","key":"6097_CR23","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1200\/JCO.18.01600","volume":"37","author":"AH Wei","year":"2019","unstructured":"Wei AH, Strickland SA Jr., Hou JZ, Fiedler W, Lin TL, Walter RB et al (2019) Venetoclax Combined with Low-Dose Cytarabine for previously untreated patients with Acute myeloid leukemia: results from a phase Ib\/II study. J Clin Oncol 37(15):1277\u20131284 https:\/\/doi.org\/10.1200\/JCO.18.01600","journal-title":"J Clin Oncol"},{"issue":"1","key":"6097_CR24","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/sj.leu.2404004","volume":"20","author":"G Juliusson","year":"2006","unstructured":"Juliusson G, Billstrom R, Gruber A, Hellstrom-Lindberg E, Hoglunds M, Karlsson K et al (2006) Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival. Leukemia 20(1):42\u201347 https:\/\/doi.org\/10.1038\/sj.leu.2404004","journal-title":"Leukemia"},{"issue":"13","key":"6097_CR25","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","volume":"361","author":"HF Fernandez","year":"2009","unstructured":"Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM et al (2009) Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 361(13):1249\u20131259 https:\/\/doi.org\/10.1056\/NEJMoa0904544","journal-title":"N Engl J Med"},{"key":"6097_CR26","doi-asserted-by":"publisher","unstructured":"Matthews A, Pratz KW (2022) Optimizing outcomes in secondary AML. Hematology Am Soc Hematol Educ Program (1): 23\u201329. https:\/\/doi.org\/10.1182\/hematology.2022000324","DOI":"10.1182\/hematology.2022000324"},{"issue":"21","key":"6097_CR27","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","volume":"375","author":"JS Welch","year":"2016","unstructured":"Welch JS, Petti AA, Miller CA, Fronick CC, O\u2019Laughlin M, Fulton RS et al (2016) TP53 and decitabine in Acute myeloid leukemia and myelodysplastic syndromes. N Engl J Med 375(21):2023\u20132036 https:\/\/doi.org\/10.1056\/NEJMoa1605949","journal-title":"N Engl J Med"},{"issue":"24","key":"6097_CR28","doi-asserted-by":"publisher","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-22-1183","volume":"28","author":"DA Pollyea","year":"2022","unstructured":"Pollyea DA, Pratz KW, Wei AH, Pullarkat V, Jonas BA, Recher C et al (2022) Outcomes in patients with poor-risk cytogenetics with or without TP53 mutations treated with Venetoclax and Azacitidine. Clin Cancer Res 28(24):5272\u20135279. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1183.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"6097_CR29","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/leu.2012.229","volume":"27","author":"AK Burnett","year":"2013","unstructured":"Burnett AK, Hills RK, Hunter AE, Milligan D, Kell WJ, Wheatley K et al (2013) The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison. Leukemia 27(1):75\u201381 https:\/\/doi.org\/10.1038\/leu.2012.229","journal-title":"Leukemia"},{"key":"6097_CR30","doi-asserted-by":"publisher","unstructured":"Burnett AK, Russell NH, Hunter AE, Milligan D, Knapper S, Wheatley K et al (2013) Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood 122(8):1384\u20131394. https:\/\/doi.org\/10.1182\/blood-2013-04-496596.","DOI":"10.1182\/blood-2013-04-496596"},{"key":"6097_CR31","doi-asserted-by":"publisher","unstructured":"Pleyer L, Burgstaller S, Girschikofsky M, Linkesch W, Stauder R, Pfeilstocker M et al (2014) Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group. Ann Hematol 93(11):1825\u20131838. https:\/\/doi.org\/10.1007\/s00277-014-2126-9.","DOI":"10.1007\/s00277-014-2126-9"},{"issue":"4","key":"6097_CR32","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1002\/ajh.23654","volume":"89","author":"S Thepot","year":"2014","unstructured":"Thepot S, Itzykson R, Seegers V, Recher C, Raffoux E, Quesnel B et al (2014) Azacitidine in untreated acute myeloid leukemia: a report on 149 patients. Am J Hematol 89(4):410\u2013416 https:\/\/doi.org\/10.1002\/ajh.23654","journal-title":"Am J Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06097-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-06097-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06097-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T01:15:09Z","timestamp":1735866909000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-06097-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,26]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["6097"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-06097-w","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,26]]},"assertion":[{"value":"28 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted with the approval of the ethics committee of The West China Hospital of Sichuan University. All procedures performed in studies involving human participants were in\u00a0accordance with the ethical standards of the institutional and national\u00a0research committee and with the 1964 Helsinki Declaration and its later\u00a0amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent to participate in this study was provided by patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare no competing financial interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}